May 30, 2012 — Tryton Medical Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced results of a patient-level pooled analysis of six-month clinical outcomes of the Tryton Side Branch Stent. Findings were presented last week in Paris at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.
Data from 905 patients treated with the Tryton stent in eight European post-marketing registries demonstrated low target lesion revascularization rates of 2.9% at six months and 4% at one year, and a low 0.5% thrombosis rate at one year.
“The consistently excellent results for the Tryton stent system in hundreds of patients should provide physicians with a great deal of confidence when choosing a strategy for treating bifurcation lesions,” said EuroPCR course director William Wijns, M.D., of the Cardiovascular Center in Aalst, Belgium. “In study after study, the Tryton stent has shown positive and predictable results for these complex cases, and this solution allows Tryton to challenge the dogma of provisional stenting for the treatment of bifurcation lesions whenever larger side branches are involved.”
Results of the pooled analysis were featured in a “Tools and Techniques” session chaired by Wijns and Martin B. Leon, M.D., of Columbia University, New York. The session featured two successful live case transmissions using the Tryton stent, including a left main bifurcation, by Eulogio Garcia, M.D., of the Hospital Clinico San Carlos in Madrid, Spain.
“For me, the key benefit of the Tryton stent is predictability,” said Garcia. “Using the Tryton, you can predict that at the end of the procedure you will have good results in both the side branch and the main vessel. In addition, there is no question that the Tryton stent has simplified the treatment of distal bifurcation of the left main.”
“Tryton Medical is emerging as the clear leader in bifurcation treatment, evidenced by an impressive presence at EuroPCR, where three live Tryton case transmissions were performed, 14 Tryton case reports discussed, and three Tryton clinical abstracts presented. We also announced our 5,000th implant, demonstrating deep adoption and routine use in clinical practice,” said Shawn P. McCarthy, president and CEO of Tryton Medical. "The Tryton Side Branch Stent represents a new growth driver in interventional cardiology. In addition to offering an innovative solution for bifurcations, our device holds potential for left main disease, which could generate a combined market opportunity of approximately 700,000 procedures annually worldwide.”
For more information: www.trytonmedical.com